">
Celltrion's biosimilar Avtozma, used to treat inflammatory diseases, was approved for the U.S. market by the Food and Drug Administration.
Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European Commission approval last August.
Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its broader strategy to expand into the original drug market.
Celltrion will reveal its dual-track strategy to juggle the development of both biosimilars and original drugs at the J.P. Morgan Healthcare Conference.
Celltrion's biosimilar Steqeyma, which mimics Johnson & Johnson's Stelara, received FDA approval for various conditions, marking the company's latest entry into the U.S. market as part of its growth strategy for biosimilars.
Celltrion is set to expend 1.5 trillion won on a new contract development and manufacturing organization subsidiary, BioSolutions, with a goal of 100 billion won per 10,000 liters.
Celltrion received recommendations of approval for four of his biosimilar products by the European Medicines Agency's screening board.
Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma
The drugmaker will use the new facility as a pipeline for existing and new product manufacturing, including biosimilars seeking regulatory approval in foreign markets.
Celltrion has invested in BioMe to develop microbiome-based treatments and accelerate the progress of investigational drug BM111, targeting multidrug resistant bacterial infections.
Korea JoongAng Daily Sitemap